Skip to content
    Nearly 30 years in clinical and development operations · Boston

    Practical AI for clinical and development operations.

    Choose the workflows worth changing, put the right controls around them, and help your team use AI in day-to-day study execution. Work directly with Kevin Anderson, a clinical and development operations leader with nearly 30 years of experience.

    Independent · Operator-led · Source-backed · Training-enabled · Conflict-aware

    decision-lattice · operator view
    In 60 seconds

    What Avery & Riley does.

    A one-minute look at how Avery & Riley helps biotech teams put AI to work in day-to-day study execution.

    Heavy AI users in 6 months · one department
    25% → 57%
    Development Operations & Clinical Operations experience
    Nearly 30 years
    Regulatory submissions and inspections
    Multiple BLAs
    Newsletter subscribers
    ~1,070

    25% to 57% is Kevin's reported result in one department over six months. It isn't company-wide or typical. Newsletter audience approximate, October 2026.

    From the work

    CRO data lake to AI agents

    A source-to-output map linking CRO operational data to sponsor-facing outputs and AI-supported workflows.

    See selected work
    Who you'll work with

    Kevin Anderson, founder

    Nearly 30 years in clinical and development operations, with multiple BLAs and regulatory inspections behind him. You work with Kevin directly.

    About Kevin
    Work with us

    Four ways to move the work forward.

    Full-time consulting

    Up to 40 hours a week

    For teams that need hands-on AI help for a defined piece of work.

    Fractional AI lead

    Part-time or interim, hands-on

    Hands-on work with your team as a fractional Head of AI or operating advisor.

    Start here

    Assessment sprint

    A prioritized plan with owners

    For clinical and development operations teams that need a defensible place to start. You get a workflow shortlist, readiness gaps, owners, risk and control considerations and a decision memo.

    Vendor advisory

    Independent, defensible shortlist

    For teams weighing AI vendors for a workflow. We look at workflow fit, vendor evidence, enterprise readiness and regulated-use controls.

    Not sure which fits? Request 20 minutes through the contact form and tell us what you're working on. We'll reply within two business days.

    Two paths, one partner

    Built for the two sides of the pharma AI conversation.

    Path 01 · Operator
    Path 02 · Vendor
    For biotech operators

    Pilot pressure, pilot sprawl, no decision spine.

    • Pilot sprawl with no clear way to prioritize
    • Vendor noise and unverifiable claims
    • Governance and validation uncertainty
    • Capability gaps across clinical and dev ops teams
    • Board and investor pressure to “have an AI plan”
    • Unclear ownership between IT, ops, and quality
    For AI companies

    Strong demo. Wrong narrative for pharma.

    • Pharma buyer complexity slowing cycles
    • Product and agent priorities driven by demos, not workflows
    • Weak enterprise readiness story
    • Messaging that resonates with technologists, not operators
    • No evidence plan for procurement and security review
    • Diligence and roadmap that won’t survive a CRO scan
    Market reality

    AI is moving faster than the decision infrastructure around it.

    Pilot sprawl
    Dozens of overlapping pilots, none scored against value, risk, or capability.
    Vendor claims
    Demos that win meetings but fail enterprise security, validation, and workflow tests.
    Governance gaps
    Risk tiers, model controls, and human review designed retroactively, if at all.
    Poor prioritization
    AI roadmaps shaped by what is loudest, not what is decision-relevant.
    How we work — from the problem outward

    Problem to measurable result. AI only where it is the simplest answer.

    1. 01
      Problem
      Start with the business problem — not the technology.
    2. 02
      Workflow
      Map how the work actually gets done today.
    3. 03
      Bottleneck
      Find where work is repeated, reconciled, searched or reformatted.
    4. 04
      Data
      Identify the data required and the system that stays authoritative.
    5. 05
      Intervention
      Choose the simplest fix — prompt, template, hub, agent, or a clearer process.
    6. 06
      Human oversight
      Define what must remain with an accountable person.
    7. 07
      Risk & control
      Proportionate controls: traceability, verification, inspection defensibility.
    8. 08
      Measurement
      Prove the gain in time, cost, quality, consistency and risk.
    Training

    Capability is the moat. We help you build it.

    Practical, operator-grade training programs for executives, development operations teams, and AI builders working inside regulated environments.

    Executive AI Briefings
    Half-day briefings for leadership teams to align on AI strategy and risk.
    Dev Ops AI Bootcamps
    Multi-week programs for clinical and development operations teams.
    AI Builder Workshops
    Hands-on labs for internal builders working on assistants, agents, and workflow design.
    Responsible AI & Governance
    Frameworks, risk tiers, and review gates for regulated AI use.
    Avery & Riley advisory session with a biotech development leadership team
    Why Avery & Riley

    Specialist focus. Operator judgment. Standards strong enough to carry a family name.

    Operator-led
    Founded by a senior development operations and clinical operations leader. Advice grounded in real execution.
    Specialist focus
    Biotech development organizations and AI companies selling to pharma. Not a generalist consultancy.
    Source-backed intelligence
    Every recommendation tied to operator interviews, vendor briefings, and documented evidence.
    Conflict-of-interest architecture
    Explicit walls between buyer, vendor, and investor engagements. Inclusion is never for sale.
    Practical training
    Capability building that survives after the engagement ends.
    Founder credibility
    Named for the middle names of the founder's daughters — a standard of judgment and integrity, not a brand exercise.
    Community

    A free community for people putting AI to work in clinical trials.

    Kevin founded the Clinical AI Innovators Network (CAIIN) so sponsors, CROs and AI vendors can learn from each other. It is free to join. Avery & Riley remains independent.

    Monthly CAIIN Call
    One live online session a month, Tuesdays from 6 to 7 pm Eastern. All levels welcome.
    Monthly newsletter
    What changed in AI for drug development, in one read.
    Prompt guides
    Ready-to-use prompts for development operations teams.
    The Pulses

    Stay close to what’s changing.

    AI Vendor Pulse and AI Pharma Pulse, published on LinkedIn.

    About 1,070 newsletter subscribers · October 2026

    AI Vendor Pulse

    Mondays

    Open on LinkedIn

    AI Pharma Pulse

    Fridays

    Open on LinkedIn

    To subscribe, sign in to LinkedIn and select Subscribe on the newsletter page.

    What's next

    Decide before the market decides for you.

    Bring us your real situation. We will tell you, candidly, where to start, what to do, and what to avoid.